Skip to content
Medical Health Aged Care

Monash to lead Australian revolution in next generation heart devices

Monash University 3 mins read

Monash University is to lead a transdisciplinary consortium to develop and commercialise a suite of revolutionary and life-changing implantable cardiac devices that, for the first time, will offer longer term solutions for all types of debilitating heart failure.

Minister for Health and Aged Care, The Hon Mark Butler, announced that the Monash-led Artificial Heart Frontiers Program, based at the Monash Alfred Baker Centre for Cardiovascular Research at The Alfred, has been awarded a $50 million grant from the Medical Research Future Fund (MRFF) towards developing and commercialising three key devices to treat the most common forms of heart failure.

Together the highly durable devices could halve deaths from heart failure and establish Australia as a world leader in the clinical trial, development and local manufacture of cardiac medical technology.

The devices comprise:

  • a wholly new miniature device, the Mini-Pump, that is implanted inside the hearts of patients who currently have no other option for treating their heart failure symptoms;
  • a new type of Left Ventricle Assist Device (LVAD) that is implanted next to a natural heart to help it pump; and
  • the Australia-US based BiVACOR’s Total Artificial Heart (TAH) that fully replaces a natural heart.

All three devices use game-changing technologies that will allow them to mimic a natural heart by automatically responding to the body’s physical demands – for the first-time offering heart failure patients a treatment that helps to keep them active.

Current devices operate with a relatively fixed blood flow rate (or pump speed) that significantly curtails activity by leaving patients out of breath.

“The Artificial Heart Frontiers Program underlines Monash’s commitment to purpose-driven research and innovation to deliver tangible and significant outcomes,” said Monash University Vice-Chancellor and President Professor Sharon Pickering.

“An MRFF grant of this scale recognises the strength of Monash’s world-leading cardiac and engineering research, and our commitment to working with partners in research, industry, government and the community to address global challenges.”

The MRFF funding will support future clinical trials at The Alfred in Melbourne and St Vincent’s Hospital Sydney.

By 2036 the project is expected to have generated a $1.8 billion benefit to Australia and Australian society, including savings to the healthcare system, an expansion in local industry in research and manufacturing, the creation of more than 2000 jobs, and providing Australians early access to clinical trials and emerging life-saving technologies.

“Heart failure is a chronic progressive condition in which patients suffer from debilitating symptoms including persistent breathlessness and fatigue, that frequently require hospitalisation at great cost to a patient’s quality of life and the health system,” said project co-lead and Director of Cardiology at The Alfred, Professor David Kaye.

“The average survival of a heart failure patient is comparable to some cancers at just five years, and is even less for patients with advanced heart failure, who are the people our devices will most benefit,” said Professor Kaye, who also leads the Monash Alfred Baker Centre for Cardiovascular Research.

“By providing for the first time an automatic physiological response, these devices will significantly improve the quality of life of patients, allowing them to complete standard daily activities without shortness of breath,” Professor Kaye said.

The development and manufacture of the devices will be the basis for a new medical device industry in Australia, comprising advanced engineering and pre-clinical evaluation, and building local capacity to support ongoing translational research in Australia’s health and medical sector.

“Central to the Frontiers Program is the creation of a complete cardiac device ecosystem in Australia encompassing research, clinical trials, commercialisation and the development of new manufacturing capabilities,” said project co-lead Associate Professor Shaun Gregory from Monash University’s Faculty of Engineering.

BiVACOR founder and the Australian designer of the TAH, Dr Daniel Timms, said the consortium was a unique opportunity to bring together life-changing innovation and product development under the strong governance and support of Australia’s pre-eminent research institutions.

“The Frontiers Project brings together an unrivalled team of world-renowned clinicians and engineers with the resources of leading universities and hospitals to focus on bettering the lives of people living with heart failure and creating a long term, vibrant industry here in Australia,” Dr Timms said.

“This project shows the power of research to foster and connect innovation across academic disciplines, organisations and industries to make a profound real-world impact,” said Professor Rebekah Brown, Deputy Vice-Chancellor (Research) and Senior Vice-President at Monash University.

About Monash cardiovascular health research

Monash University is transforming the future of cardiovascular health – for Australia and for the world. We’re committed to shaping global knowledge about cardiovascular disease, including how to better prevent it, better detect it, and better treat it. And we’re applying this knowledge across every facet of cardiovascular care.

Read thought leadership pieces about the University’s work with cardiovascular health.

- ENDS - 

MEDIA ENQUIRIES

Monash University

Tania Ewing, Media Consultant
T: +61 408 378 422  E: Taniaewing@taniaewing.com

 

For general media enquiries please contact:

Monash University Media
T: +61 3 9903 4840   E: media@monash.edu 

 

For more Monash media stories visit our news & events site: monash.edu/news

 

More from this category

  • Medical Health Aged Care, Science
  • 17/07/2024
  • 14:00
De Motu Cordis

De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

Brisbane, QLD – 17 July 2024 – De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC’s product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry powder inhaler (DPI). Catalent DPI drug delivery services offer end-to-end solutions to bring customers through the entire clinical pharma journey by leveraging the commercial…

  • Medical Health Aged Care, Women
  • 17/07/2024
  • 07:00
Monash University

Study underlines the importance of supporting primary care clinicians to deliver early medical abortion and long acting reversible contraception

The impetus for additional support and training for clinicians wanting to deliver important sexual and reproductive services has received a boost with the release of Monash University-led research. Published in BMJ – Sexual and Reproductive Health, the AusCAPPS study found that GPs, nurses and pharmacists seek peer support and online resources to deliver long-acting reversible contraception (LARC) and early medical abortion (EMA) in Australian primary care.Experienced and emerging providers of LARC and EMA sought support regarding clinical issues online from AusCAPPS, which is the Australian Contraception and Abortion Primary Care Practitioner Support Network, an evidence-based virtual community of practice launched…

  • Medical Health Aged Care
  • 17/07/2024
  • 03:11
Interrad Medical, Inc.

Interrad Medical’s SecurAcath is Superior to Standard of Care in Newly Published Randomized Controlled Clinical Study

PLYMOUTH, Minn.–BUSINESS WIRE– Interrad Medical, Inc., a privately held medical device company, announces excellent results of a clinical study published in JAMA Pediatrics titled,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.